<?xml version="1.0" encoding="UTF-8"?>
<p>In general, drug-specific RASs need to be present in at least 15% of the viruses of a given patient to reduce the likelihood of achieving SVR.[
 <xref rid="ref64" ref-type="bibr">64</xref>] Drug-specific RASs that are found at a lower frequency may not convey sufficient resistance to reduce SVR with currently available DAA regimens. The magnitude of the negative impact of RASs on treatment outcome varies according to treatment regimen and patient factors such as presence of cirrhosis and fold change decrease in potency conferred by the specific RAS(s).[
 <xref rid="ref61" ref-type="bibr">61</xref>]
</p>
